SCHEMBL7149783

SCHEMBL7149783

COc1cccc(S(=O)(=O)N(c2ccccc2)C2CCN(Cc3ccccc3)CC2)c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.54
SIGMAR1 Q99720 3/20 0.53
CHRM2 P08172 2/20 0.50
CHRM3 P20309 2/20 0.50
HTR6 P50406 1/20 0.49
OPRM1 P35372 1/20 0.49
TAS2R14 Q9NYV8 1/20 0.49
KMT2A Q03164 2/20 0.48
PGR P06401 1/20 0.48
ALDH1A1 P00352 2/20 0.48
DRD2 P14416 2/20 0.47
LMNA P02545 1/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
MCHR1 Q99705 1/20 0.46
HTR2A P28223 2/20 0.46
KDM4E B2RXH2 1/20 0.46
HTR2C P28335 1/20 0.46
HTR2B P41595 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7142524 0.94 CHRM2 (0.49) ACHESIGMAR1CHRM2CHRM3HTR6
SCHEMBL7196308 0.90 ACHE (0.51) ACHESIGMAR1CHRM2CHRM3HTR6
SCHEMBL7164480 0.90 ACHE (0.55) ACHESIGMAR1CHRM2CHRM3OPRM1
SCHEMBL7141686 0.86 CHRM2 (0.61) ACHESIGMAR1CHRM2CHRM3OPRM1
SCHEMBL7147151 0.85 HTR2A (0.58) ACHESIGMAR1CHRM2CHRM3OPRM1
SCHEMBL7176795 0.85 ALDH1A1 (0.51) ACHESIGMAR1CHRM2CHRM3OPRM1
SCHEMBL7257312 0.84 ALDH1A1 (0.56) ACHESIGMAR1CHRM2CHRM3TAS2R14
SCHEMBL7166368 0.84 ALDH1A1 (0.52) ACHESIGMAR1CHRM2CHRM3KMT2A
SCHEMBL7148472 0.84 KMT2A (0.64) ACHESIGMAR1CHRM2CHRM3KMT2A
SCHEMBL7167878 0.84 ALDH1A1 (0.49) ACHESIGMAR1CHRM2CHRM3OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176461-A1 Aminopiperidines NPS ALLELIX CORP. (CANADA CORPORATION) (CA) 2003-09-18 US claimed
EP-1296950-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS Allelix Corp. (CA) 2003-04-02 EP claimed
WO-2001081308-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS ALLELIX CORP. (CA) 2001-11-01 WO claimed
US-20030176461-A1 Aminopiperidines NPS ALLELIX CORP. (CANADA CORPORATION) (CA) 2003-09-18 US disclosed
EP-1296950-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS Allelix Corp. (CA) 2003-04-02 EP disclosed
WO-2001081308-A2 AMINOPIPERIDINES FOR USE AS GLYT-1 INHIBITORS NPS ALLELIX CORP. (CA) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176461-A1 Aminopiperidines SLC1A2, SLC6A4, SLC1A1 ACHE 826/4885SIGMAR1 223/4885CHRM2 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.